ArticleScientific reports2026

Repurposing FDA-approved drugs as multi-target neuroprotective agents for Alzheimer's disease via computational screening and experimental validation.

Khemjira Phemphunananchai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.